AN2 Therapeutics
ANTX
ANTX
51 hedge funds and large institutions have $418M invested in AN2 Therapeutics in 2023 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 16 increasing their positions, 10 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
1.49% more ownership
Funds ownership: 67.09% → 68.58% (+1.5%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Holders
51
Holding in Top 10
1
Calls
–
Puts
–
Top Buyers
| 1 | +$5.4M | |
| 2 | +$3.84M | |
| 3 | +$2.43M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.31M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.82M |
Top Sellers
| 1 | -$7.78M | |
| 2 | -$4.16M | |
| 3 | -$2.24M | |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$2.22M |
| 5 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.34M |